Peptides10 min read
Semaglutide and kidney disease: what FLOW can tell patients with diabetes
What FLOW's kidney results mean for people with type 2 diabetes, how to read the risk figures, and where the evidence remains uncertain.
Read articleBlog
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
Reading retatrutide phase 3 headlines without confusing press releases and papers
TRIUMPH-1 and TRIUMPH-2 now have published phase 3 papers. Learn how populations, estimands and follow-up change the meaning of each retatrutide headline.
Read article
Peptides9 min read
Tirzepatide versus semaglutide: what SURMOUNT-5 actually compared
SURMOUNT-5 directly compared tirzepatide and semaglutide for weight loss. Learn what the 72-week averages mean and which treatment questions remain unanswered.
Read article
Peptides9 min read
Tirzepatide for sleep apnea: why a lower AHI is only part of the story
SURMOUNT-OSA showed fewer breathing events with tirzepatide. Learn how AHI, oxygen burden, symptoms and PAP reassessment fit together.
Read article
Peptides9 min read
What SURMOUNT-4 reveals about staying on treatment
SURMOUNT-4 clarifies what happens after initial tirzepatide weight loss—and why ongoing treatment and an individualized maintenance plan are separate questions.
Read article
Peptides8 min read
Tirzepatide and heart failure: look beyond the bathroom scale
What SUMMIT found about worsening heart failure and daily function, and why its findings apply to a specific group with obesity and HFpEF.
Read article
Peptides7 min read
Tirzepatide and birth-control pills: why absorption matters
The evidence behind tirzepatide's oral-contraception precaution, its four-week windows and the separate issue of vomiting or diarrhea.
Read article
Peptides8 min read
Why athletes need a different TB-500 risk conversation
TB-500's uncertain recovery evidence does not soften its anti-doping status. Athletes need separate answers about health, eligibility, and product identity.
Read article
Peptides8 min read
Forzinity, SS-31 and longevity: what the FDA approval actually means
Forzinity's Barth syndrome approval is meaningful, but it does not establish healthy-aging or lifespan benefits. Here is what the human and animal findings show.
Read article
Peptides9 min read
What the July 2026 FDA peptide hearing changes
The July 2026 peptide hearing concerned a compounding list. Its reported recommendation, FDA's scientific review and drug approval are different decisions.
Read article
Peptides9 min read
Semaglutide and heart risk: what the SELECT trial changed
SELECT measured cardiovascular events in people with established disease. Learn what its relative and absolute results mean for treatment decisions.
Read article
Peptides9 min read
Oral semaglutide and injections: why milligrams don't tell the whole story
A tablet’s milligrams are not an injection equivalent. Follow the absorption research to understand why formulation, food and dosing conditions matter.
Read article1–12 of 320 articles